Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma-Reference-Cited by-同舟云学术

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma

Published:2014-10 Issue:10 Volume:25 Page:2020-2024
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Inwards D.J.,Fishkin P.A.,LaPlant B.R.,Drake M.T.,Kurtin P.J.,Nikcevich D.A.,Wender D.B.,Lair B.S.,Witzig T.E.

Funder

North Central Cancer Treatment Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/10/2020/23872146/mdu273.pdf

Reference27 articles.

1. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine;Romaguera;J Clin Oncol,2005

2. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma;Romaguera;Br J Haematol,2010

3. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

4. Autologous stem cell transplantation (ASCT) in first remission for patients with mantle cell lymphoma is associated with a prolonged survival;Siddiqui;Ann Oncol,2005

5. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma;Murali;Bone Marrow Transplant,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14

2. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer;Molecular Cancer;2023-08-18

3. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Mantle cell lymphoma management trends and novel agents: where are we going?;Therapeutic Advances in Hematology;2022-01

5. Synthesis of 2-Chloro-2′-Deoxyadenosine (Cladribine) and New Purine Modified Analogues;Journal of New Developments in Chemistry;2021-11-30